Last updated: 2026-09-16 11:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Ironwood Pharmaceuticals, Inc. - (IRWD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.03, with a market capitalisation of $689.05M and a P/E ratio of 5.17. Over the past 52 weeks, its price has ranged from $1.26 to $5.78. This page covers its latest market performance, valuation, price trends and company information.
$689.05M | |
$4.04 | |
$21.20 | |
$0.53 | |
$4.06 | |
174.00 | |
2.15M | |
5.17 | |
$5.78 | |
$1.26 | |
-- | |
-- |
Ironwood Pharmaceuticals, Inc. - (IRWD) is trading at $4.03 in pre-market trading as of 2026-09-16 11:17:00, down 0.74% ($0.03) from the previous close of $4.06
Pre-market trading shows how investors are pricing IRWD before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Ironwood Pharmaceuticals, Inc. - (IRWD) moved from $4.26 to $4.03, representing a decline of 5.40% ($0.23).
The stock traded between $3.94 and $4.33 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.34 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 61.3%
IRWD is currently trading at $4.03, placing it 61.3% of the way from its 52-week low of $1.26 to its 52-week high of $5.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ironwood Pharmaceuticals, Inc. - (IRWD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.